Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3011% above fair value
$10.00+0.48 (+5.04%)
Close on Nov 20, 2026Market cap $1.40BP/E –Yield –
Intellia Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Intellia Therapeutics's gross profit for the twelve months ending Dec 31, 2019 was $43.10M, up 41.6% year over year. For fiscal 2021 it was $33.05M, down 43.0% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $33.05M | -43.0% |
| FY2020 | Dec 31, 2020 | $57.99M | +34.5% |
| FY2019 | Dec 31, 2019 | $43.10M | +41.6% |
| FY2018 | Dec 31, 2018 | $30.43M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2019 | Dec 31, 2019 | $10.94M | +38.8% |
| Q3 FY2019 | Sep 30, 2019 | $10.62M | +43.3% |
| Q2 FY2019 | Jun 30, 2019 | $11.12M | – |
| Q1 FY2019 | Mar 31, 2019 | $10.43M | – |
| Q4 FY2018 | Dec 31, 2018 | $7.88M | – |
| Q3 FY2018 | Sep 30, 2018 | $7.41M | – |
See a number that looks wrong?